Cytoxan

Bristol Myers Squibb (BMS) is a leading global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases. The company maintains a robust portfolio across oncology, hematology, immunology, and cardiovascular diseases, including blockbuster therapies like Opdivo, Eliquis, and Revlimid. While Cytoxan (cyclophosphamide) is a well-known chemotherapy brand historically associated with the company, BMS has transitioned its focus toward advanced biologics and targeted therapies. The company operates a massive global research and development infrastructure and is a key player in the development of immuno-oncology and cell therapy treatments.